Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Controlled Release

• Publication date

  2016-05-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jconrel.2016.03.017PMID 26988600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity

  2015cited by this paper
• Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates

  2015cited by this paper
• Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn

  2015cited by this paper
• Targeting FcRn for the modulation of antibody dynamics.

  2015cited by this paper
• The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

  2015cited by this paper
• A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties

  2015cited by this paper
• Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety

  2015cited by this paper
• Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics.

  2015cited by this paper
• PEG - a versatile conjugating ligand for drugs and drug delivery systems.

  2014cited by this paper
• Fusion of a Short Peptide that Binds Immunoglobulin G to a Recombinant Protein Substantially Increases Its Plasma Half-Life in Mice

  2014cited by this paper
• An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein

  2014cited by this paper
• Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding*

  2014cited by this paper
• Glucose Metabolism Regulates T Cell Activation, Differentiation, and Functions

  2014cited by this paper
• pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling

  2014cited by this paper
• GSK2374697, a Novel Albumin‐Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin‐4: First Study in Humans—PK/PD and Safety

  2014cited by this paper
• Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies

  2013cited by this paper
• In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments

  2013cited by this paper
• Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?

  2013cited by this paper
• Human and Non-Human Primate Intestinal FcRn Expression and Immunoglobulin G Transcytosis

  2013cited by this paper
• Selection of Nanobodies that Target Human Neonatal Fc Receptor

  2013cited by this paper
• Abundant Intracellular IgG in Enterocytes and Endoderm Lacking FcRn

  2013cited by this paper
• Single-chain Variable Fragment Albumin Fusions Bind the Neonatal Fc Receptor (FcRn) in a Species-dependent Manner

  2013cited by this paper
• Albumin as a versatile platform for drug half-life extension.

  2013cited by this paper
• Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions

  2012cited by this paper
• Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor

  2012cited by this paper
• Monoclonal antibodies directed against human FcRn and their applications

  2012cited by this paper
• Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

  2012cited by this paper
• Glycoengineering approach to half-life extension of recombinant biotherapeutics.

  2012cited by this paper
• Fc-fusion proteins: new developments and future perspectives

  2012cited by this paper
• Neonatal Fc receptor for IgG (FcRn) expressed in the gastric epithelium regulates bacterial infection in mice

  2011cited by this paper
• Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury.

  2011cited by this paper
• Long-Acting Glucagon-Like Peptide 1 Receptor Agonists

  2011cited by this paper
• Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain*

  2010cited by this paper
• Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors

  2010cited by this paper
• IgG‐single chain Fv fusion protein therapeutic for alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey

  2010cited by this paper
• Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation.

  2009cited by this paper
• Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding*

  2009cited by this paper
• Imprinting disorders and assisted reproductive technology.

  2009cited by this paper
• Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

  2009cited by this paper
• Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs.

  2008cited by this paper
• Podocytes use FcRn to clear IgG from the glomerular basement membrane

  2008cited by this paper
• FcRn: the neonatal Fc receptor comes of age

  2007cited by this paper
• Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade

  2007cited by this paper
• Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy

  2007cited by this paper
• Neonatal FcR Expression in Bone Marrow-Derived Cells Functions to Protect Serum IgG from Catabolism1

  2007cited by this paper
• Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life.

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007cited by this paper
• Albumin binding to FcRn: distinct from the FcRn-IgG interaction.

  2006cited by this paper
• Growing bacteriophage m13 in liquid culture.

  2006cited by this paper
• A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.

  2005cited by this paper
• Expression of FcRn, the MHC class I-related receptor for IgG, in human keratinocytes.

  2005cited by this paper
• Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn1

  2004cited by this paper
• Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein.

  2004cited by this paper
• The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan

  2003cited by this paper
• Distribution of the IgG Fc Receptor, FcRn, in the Human Fetal Intestine

  2003cited by this paper
• Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier

  2002cited by this paper
• High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*

  2001cited by this paper
• MHC Class I-Related Neonatal Fc Receptor for IgG Is Functionally Expressed in Monocytes, Intestinal Macrophages, and Dendritic Cells1

  2001cited by this paper
• Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells.

  2001cited by this paper
• Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).

  2000cited by this paper
• Identification of critical IgG binding epitopes on the neonatal Fc receptor.

  1997cited by this paper
• The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.

  1996cited by this paper
• Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand.

  1994cited by this paper
• Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptor

  1994cited by this paper
• The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release.

  1993cited by this paper
• Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable

  1993cited by this paper
• An Fc receptor structurally related to MHC class I antigens

  1989cited by this paper
• Isolation and characterization of an Fc receptor from neonatal rat small intestine

  1985cited by this paper
• pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat

  1976cited by this paper

• Recent advances in targeting protein degradation for tumor immunotherapy

  2025cites this paper
• Dual-function fab-scFv fusion antibody ameliorates ulcerative colitis by targeting hFcRn-mediated colonic enrichment and TNF-α neutralization.

  2025cites this paper
• Single-chain antibody gene therapy strategy based on high-throughput screening triggers sustained antiviral activity in the body

  2024cites this paper
• pH-responsive antibodies for therapeutic applications

  2021cites this paper
• Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery.

  2021cites this paper
• Oral uptake and persistence of the FnAb-8 protein characterized by in situ radio-labeling and PET/CT imaging

  2020cites this paper
• A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities

  2020cites this paper
• Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.

  2019cites this paper
• Novel Constructs—Half-Life Extensions

  2018cites this paper
• Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13–ETA′ and the bispecific scFv [13xds16]

  2017cites this paper